Portal de Periódicos da CAPES

Obesity-related neuropathy: the new epidemic

2024; Lippincott Williams & Wilkins; Volume: 37; Issue: 5 Linguagem: Inglês

10.1097/wco.0000000000001292

1473-6551

Melissa A. Elafros, Evan L. Reynolds, Brian C. Callaghan,

Pharmacology and Obesity Treatment

Purpose of review To examine the evidence evaluating the association between obesity and neuropathy as well as potential interventions. Recent findings Although diabetes has long been associated with neuropathy, additional metabolic syndrome components, including obesity, are increasingly linked to neuropathy development, regardless of glycemic status. Preclinical rodent models as well as clinical studies are shedding light on the mechanisms of obesity-related neuropathy as well as challenges associated with slowing progression. Dietary and surgical weight loss and exercise interventions are promising, but more data is needed. Summary High-fat-diet rodent models have shown that obesity-related neuropathy is a product of excess glucose and lipid accumulation leading to inflammation and cell death. Clinical studies consistently demonstrate obesity is independently associated with neuropathy; therefore, likely a causal risk factor. Dietary weight loss improves neuropathy symptoms but not examination scores. Bariatric surgery and exercise are promising interventions, but larger, more rigorous studies are needed. Further research is also needed to determine the utility of weight loss medications and ideal timing for obesity interventions to prevent neuropathy.